Objectives: A comprehensive review was performed to investigate the effect of route of administration on medication adherence and persistence in rheumatoid arthritis (RA) and to compare adherence/persistence with oral medications between RA and a non-painful disease (dyslipidemia).
Research Design And Methods: Comprehensive database searches were performed to identify studies investigating medication adherence and/or persistence in adults with RA receiving conventional synthetic or biologic agents. Similar searches were performed for studies of patients with dyslipidemia receiving statins. Studies had to be published after 1998 in English and involve ≥6 months' follow up.
Main Outcome Measures: Adherence and persistence were compared between the different routes of drug administration in RA, and between the two diseases for oral medications.
Results: A total of 35 and 28 papers underwent data extraction for RA and dyslipidemia, respectively. Within the constraints of the analysis, adherence and persistence rates appeared broadly similar for the different routes of drug administration in RA. Adherence to oral medications was also broadly similar across the two diseases, but persistence was lower in dyslipidemia. Poor adherence has clinical consequences in both diseases: greater disease activity and risk of flare in RA, and increased serum cholesterol levels and risk of heart and cerebrovascular disease in dyslipidemia. Over 1-3 years, poor adherence to biologic RA medications led to increased resource use and medical costs but lower total direct costs due to reduced biologic drug costs. Conversely, poor adherence to dyslipidemia medications resulted in increased total direct costs. In both diseases, adherence improved with patient education/support.
Conclusions: The route of drug administration and the symptomatic (pain) nature of the disease do not appear to be dominant factors for drug adherence or persistence in RA.
Limitation: The wide range of adherence and persistence values and definitions across studies made comparisons between drug formulations and diseases difficult.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/03007995.2017.1313209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanding the clinical spectrum of 19p13.3 microduplication syndrome: a case report highlighting nephrotic syndrome and literature review.
BMC Pediatr
January 2025
Pediatric Internal Medicine, Yantai Yuhuangding Hospital, No.20 Yuhuangding East Road, Zhifu District, Yantai City, Shandong, 264000, China.
Background: Common clinical findings in patients with 19p13.3 duplication include intrauterine growth restriction, intellectual disability, developmental delay, microcephaly, and distinctive facial features. In this study, we report the case of a patient with 19p13.
View Article and Find Full Text PDFSecular trends of physical fitness for college students in Anhui Province over the past decade.
BMC Public Health
January 2025
School of Physical Education, Chizhou University, Chizhou, 247000, China.
Background: Since the beginning of the 21st century, China's economy has experienced rapid growth, resulting in a steady improvement in its citizens' living standards. However, alongside the emergence of modern civilization-related health issues, the overall physical fitness of the population has been declining. In the final year of 2019, a global COVID-19 pandemic emerged and persisted for three years, causing a significant diminution in human physical well-being.
View Article and Find Full Text PDFImpacted lower third molar classification and difficulty index assessment: comparisons among dental students, general practitioners and deep learning model assistance.
BMC Oral Health
January 2025
Bangkok Hospital Dental Center Holistic Care and Dental Implant, Bangkok Hospital, Bangkok, 10310, Thailand.
Background: Assessing the difficulty of impacted lower third molar (ILTM) surgical extraction is crucial for predicting postoperative complications and estimating procedure duration. The aim of this study was to evaluate the effectiveness of a convolutional neural network (CNN) in determining the angulation, position, classification and difficulty index (DI) of ILTM. Additionally, we compared these parameters and the time required for interpretation among deep learning (DL) models, sixth-year dental students (DSs), and general dental practitioners (GPs) with and without CNN assistance.
View Article and Find Full Text PDFLipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.
Drugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
The wonders of anticoagulation.
Front Cardiovasc Med
January 2025
Thrombosis Expertise Center, Maastricht University Medical Centre, Maastricht, Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!